Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AgfiledCriticalNovartis Ag
Publication of ECSP045163ApublicationCriticalpatent/ECSP045163A/en
Una composición farmacéutica sólida para administración oral, la cual comprende tegaserod en forma de base o de sal, en una cantidad de hasta el 10 por ciento en peso, un agente de volumen en una cantidad del 70 al 90 por ciento en peso, un desintegrante en una cantidad menor al 15 por ciento en peso, un abrillantador, y un lubricante.A solid pharmaceutical composition for oral administration, which comprises tegaserod in base or salt form, in an amount of up to 10 percent by weight, a bulking agent in an amount of 70 to 90 percent by weight, a disintegrant in an amount less than 15 percent by weight, a brightener, and a lubricant.
ECSP0451632001-12-212004-06-18
PHARMACEUTICAL COMPOSITIONS OF PARTIAL AGONIST 5HT4
ECSP045163A
(en)
Pharmaceutical compositions comprising a basic or acidic drug compound, a sufactant and a physiologically acceptable water-soluble acid or base, respectively.